CAH vs. CYTK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at CAH and CYTK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | CAH | CYTK |
|---|---|---|
| Company Name | Cardinal Health, Inc. | Cytokinetics, Incorporated |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 36.52 billion USD | 4.47 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | August 4, 1983 | April 30, 2004 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of CAH and CYTK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | CAH | CYTK |
|---|---|---|
| 5-Day Price Return | 1.82% | -3.62% |
| 13-Week Price Return | -0.59% | 21.37% |
| 26-Week Price Return | 20.64% | -10.33% |
| 52-Week Price Return | 39.31% | -33.90% |
| Month-to-Date Return | -1.46% | -0.85% |
| Year-to-Date Return | 29.32% | -20.66% |
| 10-Day Avg. Volume | 3.13M | 1.78M |
| 3-Month Avg. Volume | 2.31M | 1.71M |
| 3-Month Volatility | 23.34% | 42.40% |
| Beta | 0.73 | 0.55 |
Profitability
Return on Equity (TTM)
CAH
37.17%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
CAH’s Return on Equity of 37.17% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
CYTK
-132.03%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
CYTK has a negative Return on Equity of -132.03%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
CAH
0.70%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
Falling into the lower quartile for the Health Care Providers & Services industry, CAH’s Net Profit Margin of 0.70% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
CYTK
-707.17%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
CYTK has a negative Net Profit Margin of -707.17%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
CAH
1.02%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
CAH’s Operating Profit Margin of 1.02% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
CYTK
-637.96%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
CYTK has a negative Operating Profit Margin of -637.96%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | CAH | CYTK |
|---|---|---|
| Return on Equity (TTM) | 37.17% | -132.03% |
| Return on Assets (TTM) | 3.23% | -45.52% |
| Net Profit Margin (TTM) | 0.70% | -707.17% |
| Operating Profit Margin (TTM) | 1.02% | -637.96% |
| Gross Profit Margin (TTM) | 3.67% | -- |
Financial Strength
Current Ratio (MRQ)
CAH
0.94
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
CAH’s Current Ratio of 0.94 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
CYTK
6.76
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
CYTK’s Current Ratio of 6.76 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
CAH
5.65
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
With a Debt-to-Equity Ratio of 5.65, CAH operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
CYTK
6.03
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 6.03, CYTK operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
CAH
10.77
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
CAH’s Interest Coverage Ratio of 10.77 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
CYTK
-16.50
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
CYTK has a negative Interest Coverage Ratio of -16.50. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | CAH | CYTK |
|---|---|---|
| Current Ratio (MRQ) | 0.94 | 6.76 |
| Quick Ratio (MRQ) | 0.44 | 6.61 |
| Debt-to-Equity Ratio (MRQ) | 5.65 | 6.03 |
| Interest Coverage Ratio (TTM) | 10.77 | -16.50 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
CAH
1.37%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Yield of 1.37% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
CAH
31.65%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
CAH’s Dividend Payout Ratio of 31.65% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
CYTK
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
CYTK has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | CAH | CYTK |
|---|---|---|
| Dividend Yield (TTM) | 1.37% | 0.00% |
| Dividend Payout Ratio (TTM) | 31.65% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
CAH
23.18
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
CAH’s P/E Ratio of 23.18 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
CYTK
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for CYTK is currently unavailable.
Price-to-Sales Ratio (TTM)
CAH
0.16
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, CAH’s P/S Ratio of 0.16 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
CYTK
52.60
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
CYTK’s P/S Ratio of 52.60 is in the upper echelon for the Biotechnology industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
CAH
14.54
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
At 14.54, CAH’s P/B Ratio is at an extreme premium to the Health Care Providers & Services industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
CYTK
58.48
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
At 58.48, CYTK’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | CAH | CYTK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 23.18 | -- |
| Price-to-Sales Ratio (TTM) | 0.16 | 52.60 |
| Price-to-Book Ratio (MRQ) | 14.54 | 58.48 |
| Price-to-Free Cash Flow Ratio (TTM) | 8.85 | 78.61 |